Latest Insider Transactions at Certara, Inc. (CERT)
This section provides a real-time view of insider transactions for Certara, Inc. (CERT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Certara, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Certara, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
SELL
Open market or private sale
|
Direct |
5,409
-9.75%
|
$59,499
$11.03 P/Share
|
|
Oct 04
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,742
-3.04%
|
$17,420
$10.99 P/Share
|
|
Oct 04
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
BUY
Exercise of conversion of derivative security
|
Direct |
7,151
+11.11%
|
-
|
|
Sep 09
2024
|
Leif E Pedersen PRESIDENT, CHIEF COMMERCAL OFF |
SELL
Open market or private sale
|
Direct |
51,224
-33.94%
|
$563,464
$11.29 P/Share
|
|
Jul 01
2024
|
Robert Aspbury PRESIDENT, SCIENTIFIC SOFTWARE |
SELL
Payment of exercise price or tax liability
|
Direct |
862
-0.3%
|
$11,206
$13.85 P/Share
|
|
May 21
2024
|
Matthew M Walsh |
BUY
Exercise of conversion of derivative security
|
Direct |
8,663
+4.46%
|
-
|
|
May 21
2024
|
Nancy Killefer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,663
+26.39%
|
-
|
|
May 21
2024
|
Rosemary A Crane |
BUY
Exercise of conversion of derivative security
|
Direct |
8,663
+32.51%
|
-
|
|
May 21
2024
|
Cynthia Collins |
BUY
Exercise of conversion of derivative security
|
Direct |
8,663
+26.39%
|
-
|
|
May 21
2024
|
James E Cashman Iii |
BUY
Exercise of conversion of derivative security
|
Direct |
8,663
+1.86%
|
-
|
|
May 21
2024
|
Eran Broshy |
BUY
Exercise of conversion of derivative security
|
Direct |
8,663
+27.34%
|
-
|
|
Apr 02
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
SELL
Open market or private sale
|
Direct |
14,427
-4.07%
|
$245,259
$17.24 P/Share
|
|
Apr 01
2024
|
Nicolette D Sherman CHIEF HUMAN RESOURCES OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,578
-5.34%
|
$43,826
$17.88 P/Share
|
|
Apr 01
2024
|
Nicolette D Sherman CHIEF HUMAN RESOURCES OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,219
+14.54%
|
-
|
|
Apr 01
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
6,955
-3.73%
|
$118,235
$17.88 P/Share
|
|
Apr 01
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
BUY
Exercise of conversion of derivative security
|
Direct |
16,498
+11.34%
|
-
|
|
Apr 01
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,000
-1.7%
|
$54,000
$18.0 P/Share
|
|
Apr 01
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
6,244
-1.19%
|
$106,148
$17.88 P/Share
|
|
Apr 01
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
13,295
+3.63%
|
-
|
|
Apr 01
2024
|
Robert Aspbury PRESIDENT, SCIENTIFIC SOFTWARE |
SELL
Payment of exercise price or tax liability
|
Direct |
10,625
-1.22%
|
$180,625
$17.88 P/Share
|
|
Apr 01
2024
|
Robert Aspbury PRESIDENT, SCIENTIFIC SOFTWARE |
BUY
Exercise of conversion of derivative security
|
Direct |
16,498
+2.75%
|
-
|
|
Apr 01
2024
|
John E Gallagher CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,077
-25.79%
|
$154,309
$17.88 P/Share
|
|
Apr 01
2024
|
John E Gallagher CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
27,295
+42.95%
|
-
|
|
Apr 01
2024
|
Leif E Pedersen PRESIDENT, CHIEF COMMERCAL OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
5,951
-1.35%
|
$101,167
$17.88 P/Share
|
|
Apr 01
2024
|
Leif E Pedersen PRESIDENT, CHIEF COMMERCAL OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
16,498
+5.22%
|
-
|
|
Apr 01
2024
|
William F Feehery CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
42,629
-0.63%
|
$724,693
$17.88 P/Share
|
|
Apr 01
2024
|
William F Feehery CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
69,799
+1.52%
|
-
|
|
Mar 05
2024
|
Nicolette D Sherman CHIEF HUMAN RESOURCES OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,373
-11.25%
|
$42,714
$18.88 P/Share
|
|
Mar 05
2024
|
Nicolette D Sherman CHIEF HUMAN RESOURCES OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,600
+23.84%
|
-
|
|
Mar 05
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
3,660
-2.11%
|
$65,880
$18.88 P/Share
|
|
Mar 05
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
10,765
+5.85%
|
-
|
|
Mar 05
2024
|
William F Feehery CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
17,557
-0.78%
|
$316,026
$18.88 P/Share
|
|
Mar 05
2024
|
William F Feehery CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
59,799
+2.6%
|
-
|
|
Mar 05
2024
|
Leif E Pedersen PRESIDENT, CHIEF COMMERCAL OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
4,050
-2.8%
|
$72,900
$18.88 P/Share
|
|
Mar 05
2024
|
Leif E Pedersen PRESIDENT, CHIEF COMMERCAL OFF |
BUY
Grant, award, or other acquisition
|
Direct |
15,548
+9.72%
|
-
|
|
Mar 05
2024
|
Robert Aspbury PRESIDENT, SCIENTIFIC SOFTWARE |
SELL
Payment of exercise price or tax liability
|
Direct |
7,311
-1.27%
|
$131,598
$18.88 P/Share
|
|
Mar 05
2024
|
Robert Aspbury PRESIDENT, SCIENTIFIC SOFTWARE |
BUY
Grant, award, or other acquisition
|
Direct |
15,549
+2.61%
|
-
|
|
Mar 04
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,000
-1.81%
|
$54,000
$18.28 P/Share
|
|
Feb 20
2024
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
SELL
Open market or private sale
|
Direct |
5,000
-8.34%
|
$90,000
$18.0 P/Share
|
|
Feb 12
2024
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
6,000
-3.5%
|
$108,000
$18.0 P/Share
|
|
Dec 26
2023
|
Richard M. Traynor SVP AND GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
6,000
-3.38%
|
$108,000
$18.0 P/Share
|
|
Sep 11
2023
|
Leif E Pedersen PRESIDENT, CHIEF COMMERCAL OFF |
SELL
Open market or private sale
|
Direct |
51,224
-28.44%
|
$717,136
$14.6 P/Share
|
|
Aug 22
2023
|
Eran Broshy |
BUY
Open market or private purchase
|
Direct |
4,807
+25.08%
|
$72,105
$15.8 P/Share
|
|
Aug 21
2023
|
Eran Broshy |
BUY
Open market or private purchase
|
Direct |
193
+1.98%
|
$3,088
$16.1 P/Share
|
|
Aug 01
2023
|
Nicolette D Sherman CHIEF HUMAN RESOURCES OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,057
-6.8%
|
$20,083
$19.47 P/Share
|
|
Jun 30
2023
|
Robert Aspbury PRESIDENT, SCIENTIFIC SOFTWARE |
SELL
Payment of exercise price or tax liability
|
Direct |
862
-0.31%
|
$15,516
$18.19 P/Share
|
|
Jun 05
2023
|
Patrick F Smith PRESIDENT, DRUG DEV SOLUTIONS |
SELL
Open market or private sale
|
Direct |
19,104
-24.16%
|
$401,184
$21.55 P/Share
|
|
May 23
2023
|
Eran Broshy |
BUY
Exercise of conversion of derivative security
|
Direct |
9,360
+50.0%
|
-
|
|
May 23
2023
|
Rosemary A Crane |
BUY
Exercise of conversion of derivative security
|
Direct |
9,324
+50.0%
|
-
|
|
May 17
2023
|
Matthew M Walsh |
BUY
Exercise of conversion of derivative security
|
Direct |
9,067
+4.87%
|
-
|